Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Fate Therapeutics, Inc.

Overview
Date Founded

2007

Headquarters

3535 General Atomics Court, Suite 200, San Diego, CA, 92121, USA

Type of Company

Public

Employees (Worldwide)

104

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Fate Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

General Counsel & Secretary

Chief Development Officer

Chief Scientific Officer

Senior Vice President-Corporate Development

Senior Vice President-Technical Operations

Senior Vice President-Clinical Translation

Vice President, Clinical Development

Vice President of Regulatory Affairs, CMC & QA

Board of Directors

Founder at Fate Therapeutics, Inc.

Professional at Fate Therapeutics, Inc.

President & Chief Executive Officer at Dewpoint Therapeutics, Inc.

Founder at Fate Therapeutics, Inc.

Founding Member at Redmile Group LLC

Chief Scientific Officer & Executive Vice President-Research at Gritstone Oncology, Inc.

Paths to Fate Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Fate Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Redmile Group invests primarily in U.S. and non-U.S. healthcare companies. While the partnerships and funds generally invest in public equities, these investtments may be in illiquid, publicly-quoted securities, investments may be made in illiquid, publicly-quoted securities. The partnerships or funds may invest in private companies and non-equity asset classes when Redmile Group believes such investments offer a superior risk-reward. The firm may also invest in fields related to healthcare where due diligence shows that the healthcare assets are the driving force behind value creation and may also invest in other sectors from time to time.While Redmile Group mainly invests public equities of healthcare companies, they gennerally have broad and flexible investment authority. To maintain flexibility and capitalize on investment opportunities as they arise, the Redmile Group isn't required to invest any particular percentage of managed portfolios in any particular type of investment or region, and the amount of the portfolios which is invested in any type of investment or which is weighted in different countries or different sectors can change at any time. As such, investments may at any time include long or short positions in U.S. or non-U.S. publicly traded or privately issued common stocks, preferred stocks, stock warrants and rights, bonds, notes or other debentures or debt participations, convertible bonds, convertible preference shares, fund interests, swaps, options (including options on stock market indices), futures contracts, commodities, forward contracts and other securities or financial instruments including those of investment companies.^

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

Casdin Capital focuses on investments in disruptive businesses and is positioned to capitalize off an underappreciated, disruptive technology shift currently unfolding in the life sciences and healthcare industry. They consider investment opportunities that span the entire healthcare continuum and into sectors such as agriculture, industrial manufacturing and traditional information technology.

Recent Transactions
Details Hidden

Fate Therapeutics, Inc. issued . USD Common Stock

Details Hidden

Fate Therapeutics, Inc. issued USD Common Stock

Details Hidden

Fate Therapeutics, Inc. raised money in a private placement transaction

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Escrow Agent

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Investment Advisor

Advised onFate Therapeutics, Inc. raised money in a private placement transaction

Legal Advisor

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Legal Advisor

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Associate

Advised onFate Therapeutics, Inc. issued . USD Common Stock

Advisors & Consultants
Legal Advisor

Chairman, Silicon Valley at Goodwin Procter LLP

Legal Advisor

National Co-Chair, Life Sciences Practice at Goodwin Procter LLP

Consultant

Chief Medical Officer at ORIC Pharmaceuticals, Inc.

Clients

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$1.14B
Total Enterprise Value
$535M
Earnings Per Share
$-1.19
Revenue
$4.74M
Total Debt
$14.9M
Total Equity
$160M
Net Profit
$-66.6M
EBITDA
$-65.9M
EBITDAMargin
-1,390.04%
TEVNet Income
-8.03x
Debt TEV
0.03x
Enterprise Value Sales
112.84x
Investors
Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Details Hidden

The California Institute for Regenerative Medicine ("The Institute" or "CIRM") was established in early 2005 following the passage of Proposition 71, the California Stem Cell Research and Cures Initiative. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The mission of CIRM is to support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury.

Details Hidden

OVP is an active manager which provides equity financing for seed and early-stage capital requirements. The firm targets companies operating in the technology services and healthcare technology sector, and industries such as information technology services, biotechnology and alternative power generation. OVP initially invests between USD 1 and 5 million in companies located in the United States. The firm looks to take minority positions in its investments.

Suppliers
Indiana University BLOOMINGTON, INDIANA

Indiana University is a major multi-campus public research institution, grounded in the liberal arts and sciences, and a world leader in professional, medical, and technological education. Indiana University’s mission is to provide broad access to undergraduate, graduate, and continuing education for students throughout Indiana, the United States, and the world, as well as outstanding academic and cultural programs and student services. Indiana University seeks to create dynamic partnerships with the state and local communities in economic, social, and cultural development and to offer leadership in creative solutions for 21st century problems. Indiana University strives to achieve full diversity, and to maintain friendly, collegial, and humane environments, with a strong commitment to academic freedom.

The Children's Medical Center Corp. Hospitals & Patient Services | Boston, MA

The Children's Medical Center Corp. operates as a non-profit hospital and research center. The company was founded in 1959 and is headquartered in Boston, MA.

The Scripps Research Institute Biotechnology | La Jolla, CA

The Scripps Research Institute (TSRI), one of the world's largest, private, non-profit research organizations, stands at the forefront of basic biomedical science, a vital segment of medical research that seeks to comprehend the most fundamental processes of life. Over the last decades, the institute has established a lengthy track record of major contributions to the betterment of health and the human condition. The institute — which is located on campuses in La Jolla, California, and Jupiter, Florida — has become internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases, virology, and synthetic vaccine development. Particularly significant is the institute's study of the basic structure and design of biological molecules; in this arena TSRI is among a handful of the world's leading centers. The institute’s educational programs are also top-rate. The Kellogg School of Science and Technology is currently ranked among the best in the nation in its fields of biology and chemistry. Rather than isolating faculty members, students, and laboratories into separate and distinct disciplines, as is generally prescribed in universities, a cooperative, collaborative spirit is encouraged and embraced. While the level of scientific investigation is intense, the atmosphere is collegial, relaxed, and informal. Technicians, postdoctoral fellows, graduate students, and administrative support staff all are considered part of the team and are given the latitude and responsibility to accomplish their tasks so as to serve the best interests of science. The pursuit of scientific excellence is paramount and all efforts are directed toward that end. The bulk of the institute's funding is derived from the National Institutes of Health and other federal agencies. In today's environment of increasing competition for shrinking federal dollars, however, collaborative industrial partnerships with leading pharmaceutical companies provide additional funding in several areas key to the organization's research objectives. The Scripps Research Institute's adherence to the highest scientific standards, emphasis on a multidisciplinary approach to problem solving, participation in the perpetuation of knowledge through education, and continual pursuit of research excellence provide an unparalleled scientific environment.

Competitors
Celgene Corp. Pharmaceuticals

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Intrexon Corp. Biotechnology - Germantown , MD

Intrexon Corp. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

AbbVie, Inc. Pharmaceuticals - North Chicago , IL

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Fate Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Fate Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Fate Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/fate-therapeutics-inc-883872
  • https://relationshipscience.com/organization/fate-therapeutics-inc-883872